184 related articles for article (PubMed ID: 35382859)
1. Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.
Song Z; Liu X; Zhang W; Luo Y; Xiao H; Liu Y; Dai G; Hong J; Li A
J Transl Med; 2022 Apr; 20(1):157. PubMed ID: 35382859
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
Granzow M; Schierwagen R; Klein S; Kowallick B; Huss S; Linhart M; Mazar IG; Görtzen J; Vogt A; Schildberg FA; Gonzalez-Carmona MA; Wojtalla A; Krämer B; Nattermann J; Siegmund SV; Werner N; Fürst DO; Laleman W; Knolle P; Shah VH; Sauerbruch T; Trebicka J
Hepatology; 2014 Jul; 60(1):334-48. PubMed ID: 24619965
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
4. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
Zhang Y; Liang R; Chen CW; Mallano T; Dees C; Distler A; Reich A; Bergmann C; Ramming A; Gelse K; Mielenz D; Distler O; Schett G; Distler JHW
Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
[TBL] [Abstract][Full Text] [Related]
5. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
6. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells
Li Z; Ding Q; Ling LP; Wu Y; Meng DX; Li X; Zhang CQ
World J Gastroenterol; 2018 Feb; 24(7):819-832. PubMed ID: 29467552
[TBL] [Abstract][Full Text] [Related]
7. P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts.
Dou C; Liu Z; Tu K; Zhang H; Chen C; Yaqoob U; Wang Y; Wen J; van Deursen J; Sicard D; Tschumperlin D; Zou H; Huang WC; Urrutia R; Shah VH; Kang N
Gastroenterology; 2018 Jun; 154(8):2209-2221.e14. PubMed ID: 29454793
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
Torres S; Ortiz C; Bachtler N; Gu W; Grünewald LD; Kraus N; Schierwagen R; Hieber C; Meier C; Tyc O; Joseph Brol M; Uschner FE; Nijmeijer B; Welsch C; Berres ML; Garcia-Ruiz C; Fernandez-Checa JC; Trautwein C; Vogl TJ; Zeuzem S; Trebicka J; Klein S
Hepatology; 2023 Apr; 77(4):1228-1240. PubMed ID: 35993369
[TBL] [Abstract][Full Text] [Related]
9. Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
Nakamura I; Zakharia K; Banini BA; Mikhail DS; Kim TH; Yang JD; Moser CD; Shaleh HM; Thornburgh SR; Walters I; Roberts LR
PLoS One; 2014; 9(4):e92273. PubMed ID: 24710173
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor β selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells.
Zhang B; Zhang CG; Ji LH; Zhao G; Wu ZY
J Gastroenterol Hepatol; 2018 Mar; 33(3):747-755. PubMed ID: 28884481
[TBL] [Abstract][Full Text] [Related]
11. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
13. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic protein-7 represses hepatic stellate cell activation and liver fibrosis
Zou GL; Zuo S; Lu S; Hu RH; Lu YY; Yang J; Deng KS; Wu YT; Mu M; Zhu JJ; Zeng JZ; Zhang BF; Wu X; Zhao XK; Li HY
World J Gastroenterol; 2019 Aug; 25(30):4222-4234. PubMed ID: 31435175
[TBL] [Abstract][Full Text] [Related]
15. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
16. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.
Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H
Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480
[No Abstract] [Full Text] [Related]
17. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
Yang S; Luo C; Gu Q; Xu Q; Wang G; Sun H; Qian Z; Tan Y; Qin Y; Shen Y; Xu X; Chen SH; Chan CC; Wang H; Mao M; Fang DD
Oncotarget; 2016 Feb; 7(5):5461-9. PubMed ID: 26701727
[TBL] [Abstract][Full Text] [Related]
18. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
19. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.
Febvre-James M; Lecureur V; Fardel O
Inflamm Res; 2020 Jan; 69(1):51-62. PubMed ID: 31654094
[TBL] [Abstract][Full Text] [Related]
20. A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
